Source Natural

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE679C01027
  • NSEID:
  • BSEID: 531398
INR
129.00
2 (1.57%)
BSENSE

Feb 13

BSE+NSE Vol: 1.23 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.23 k (-57.14%) Volume

Shareholding (Dec 2025)

FII

0.00%

Held by 0 FIIs

DII

0.00%

Held by 0 DIIs

Promoter

74.37%

Who are the top shareholders of the Source Natural?

06-Jun-2025

The top shareholder of Source Natural is Sriveda Sattva Private Limited, owning 74.37% of the shares, followed by public shareholder Guttikonda Vara Lakshmi with 2.96%. Individual investors hold 19.98%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Source Natural include Sriveda Sattva Private Limited, which holds a significant 74.37% of the shares, making it the largest promoter. The highest public shareholder is Guttikonda Vara Lakshmi, who owns 2.96% of the shares. Additionally, individual investors collectively hold 19.98% of the company's shares. There are currently no mutual funds or foreign institutional investors holding shares in the company.

View full answer

Who are in the management team of Source Natural?

06-Jun-2025

As of March 2023, the management team of Source Natural includes Narayana Narasimhan (Chairman), Arvind Varchaswi N (Managing Director), Tejagna Kashmira Katpitia (Executive Director), and several independent directors: Gowra Srinivas, Chandrakant Laxminarayan Rathi, Sriram Chandrasekaran, and Bharathy. Each member contributes to the company's governance and management.

As of March 2023, the management team of Source Natural includes the following individuals:<BR><BR>1. **Narayana Narasimhan** - Chairman & Non Executive Director<BR>2. **Arvind Varchaswi N** - Managing Director<BR>3. **Tejagna Kashmira Katpitia** - Executive Director & Wholetime Director<BR>4. **Gowra Srinivas** - Independent Director<BR>5. **Chandrakant Laxminarayan Rathi** - Independent Director<BR>6. **Sriram Chandrasekaran** - Independent Director<BR>7. **Bharathy** - Independent Director<BR><BR>Each member plays a significant role in the governance and management of the company.

View full answer

Has Source Natural declared dividend?

06-Jun-2025

No Dividend History Available

Who are the peers of the Source Natural?

03-Jun-2025

Source Natural's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs, Ind-Swift, and Ajooni Biotech. Source Natural has a 1-year return of 105.50%, outperforming its peers, with Divi's Lab showing the highest return at 51.96% and Bharat Immunolog the lowest at -9.01%.

Peers: The peers of Source Natural are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Bharat Immunolog, Mercury Labs, Makers Labs., Ind-Swift, and Ajooni Biotech.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Source Natural, while Average management risk is found at Mercury Labs. Below Average management risk is noted for Bharat Immunolog, Makers Labs., and Ajooni Biotech, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is seen in Source Natural, Divi's Lab., Torrent Pharma, Bharat Immunolog, Mercury Labs, Makers Labs., and Ajooni Biotech, and the rest. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, while Good capital structure is noted for Source Natural and Torrent Pharma, and Below Average capital structure is observed in Bharat Immunolog, Mercury Labs, Makers Labs., and Ind-Swift.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Bharat Immunolog at -9.01%. Source Natural's 1-year return is 105.50%, which is significantly higher than both. Additionally, the peers with negative six-month returns include Mercury Labs, Bharat Immunolog, and Ind-Swift.

View full answer

What is the technical trend for Source Natural?

09-Jun-2025

As of June 2, 2025, Source Natural's technical trend is neutral with mixed signals, showing mildly bullish indicators on weekly MACD and Bollinger Bands, but mildly bearish on monthly MACD and daily moving averages.

As of 2 June 2025, the technical trend for Source Natural has changed from mildly bullish to sideways. The weekly MACD indicates a mildly bullish stance, while the monthly MACD is mildly bearish, suggesting mixed signals across time frames. The Bollinger Bands are mildly bullish on both weekly and monthly charts, supporting a potential upward movement. However, daily moving averages are mildly bearish, indicating short-term weakness. The KST remains bullish on both weekly and monthly, and Dow Theory shows a mildly bullish trend weekly but mildly bearish monthly. Overall, the current technical stance is neutral with moderate strength, driven by conflicting signals from various indicators.

View full answer

What does Source Natural do?

17-Jul-2025

Source Natural Foods & Herbal Supplements Ltd specializes in allopathic and ayurvedic formulations within the pharmaceuticals and biotechnology sector. As of March 2025, it reported net sales of 161 Cr and a net profit of 6 Cr, with a market cap of INR 100 Cr.

Overview:<BR>Source Natural Foods & Herbal Supplements Ltd operates in the pharmaceuticals and biotechnology industry, focusing on providing allopathic and ayurvedic formulations.<BR><BR>History:<BR>The company was incorporated in 1995 as Inwinex Pharmaceuticals Limited and changed its name to Source Natural Foods & Herbal Supplements Limited in 2011-12. The latest quarterly results reported net sales and profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 161 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 6 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 100 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 33.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 14.04%<BR>- Price to Book: 4.71<BR><BR>Contact Details:<BR>Address: 201 2nd Floor Sumeru Towers, 54/46 39 Jayanagar 4th Block Bangaluru Karnataka : 560041 <BR>Tel: 91-80-26087733 <BR>Email: info@source-natural.com <BR>Website: http://www.source-natural.com

View full answer

How big is Source Natural?

24-Jul-2025

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, with recent net sales of 44.94 Cr and a net profit of 2.91 Cr. Shareholder's funds are 19.45 Cr, and total assets amount to 23.65 Cr.

As of 24th July, Source Natural Foods & Herbal Supplements Ltd has a market capitalization of 93.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 44.94 Cr and a Net Profit of 2.91 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 19.45 Cr and Total Assets of 23.65 Cr.

View full answer

Is Source Natural overvalued or undervalued?

14-Nov-2025

As of November 13, 2025, Source Natural is fairly valued with a PE ratio of 29.30 and a PEG ratio of 0.46, indicating reasonable valuation compared to peers, despite a 41.67% decline in stock performance over the past year.

As of 13 November 2025, the valuation grade for Source Natural has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 29.30, an EV to EBITDA of 16.59, and a PEG ratio of 0.46. These ratios suggest that while the company has growth potential, its current valuation aligns with its earnings and growth prospects.<BR><BR>In comparison to its peers, Source Natural's valuation appears reasonable. For instance, Sun Pharma has a significantly higher PE ratio of 36.15, while Cipla, considered attractive, has a PE of 22.65. The notable outperformance of Source Natural's PEG ratio at 0.46 compared to peers like Divi's Lab, which has a PEG of 1.99, further supports the conclusion that Source Natural is fairly valued. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 41.67% compared to the Sensex's gain of 8.74%, reinforcing the notion that the stock may not be undervalued at this time.

View full answer

How has been the historical performance of Source Natural?

25-Nov-2025

Source Natural has demonstrated significant growth in net sales and profitability, with net sales increasing from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, and profit after tax rising from 2.12 Cr to 2.90 Cr during the same period. The company's total assets also grew from 21.45 Cr to 35.83 Cr, indicating a positive trend in financial performance.

Answer:<BR>The historical performance of Source Natural shows a significant upward trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Source Natural's net sales have increased from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25, demonstrating robust growth. The total operating income followed a similar trajectory, rising from 19.77 Cr in Mar'23 to 44.92 Cr in Mar'25. Operating profit, excluding other income, also saw an increase, reaching 5.15 Cr in Mar'25 from 3.56 Cr in Mar'23. Profit before tax improved from 2.74 Cr in Mar'23 to 3.58 Cr in Mar'25, while profit after tax rose from 2.12 Cr to 2.90 Cr in the same period. The company's earnings per share (EPS) increased from 3.29 in Mar'23 to 4.5 in Mar'25, reflecting enhanced shareholder value. On the balance sheet, total assets grew from 21.45 Cr in Mar'23 to 35.83 Cr in Mar'25, alongside total liabilities which increased from 21.45 Cr to 35.83 Cr. The cash flow from operating activities remained stable, with a net cash inflow of 0.00 Cr in Mar'25, while cash and cash equivalents at the end of the period were 7.00 Cr, consistent with the previous year. Overall, Source Natural has shown a positive trend in sales, profitability, and asset growth over the past few years.

View full answer

Should I buy, sell or hold Source Natural Foods & Herbal Supplements Ltd?

06-Feb-2026

When is the next results date for Source Natural Foods & Herbal Supplements Ltd?

10-Feb-2026

The next results date for Source Natural Foods & Herbal Supplements Ltd is 14 February 2026.

The next results date for Source Natural Foods & Herbal Supplements Ltd is scheduled for 14 February 2026.

View full answer

Are Source Natural Foods & Herbal Supplements Ltd latest results good or bad?

14-Feb-2026

Source Natural Foods & Herbal Supplements Ltd's latest results show strong revenue growth of 65.20% year-on-year, reaching ₹16.95 crores, but profitability is a concern with declining operating and profit margins, indicating challenges in sustaining bottom-line profitability despite top-line growth.

The latest results for Source Natural Foods & Herbal Supplements Ltd present a mixed picture. On one hand, the company achieved impressive revenue growth, with a 65.20% increase year-on-year, reaching ₹16.95 crores in Q2 FY26. This reflects strong market traction and demand for its organic products. Additionally, the net profit showed a positive sequential growth of 11.11%, rising to ₹0.70 crores.<BR><BR>However, profitability metrics are concerning. The operating margin has significantly compressed to 8.02%, down from 10.33% in the previous quarter and 13.45% a year ago. This decline in margins, despite robust revenue growth, raises questions about the company's ability to maintain profitability as it scales operations. The profit after tax margin also fell to 4.13%, down from 5.21% in the previous quarter and 8.19% in the same quarter last year.<BR><BR>Overall, while the revenue growth is commendable, the erosion of profit margins and declining net profit year-on-year indicate that the company faces significant challenges in converting its top-line growth into sustainable bottom-line profitability. This divergence between growth and profitability suggests that the results are not entirely positive and warrant caution moving forward.

View full answer

Why is Source Natural Foods & Herbal Supplements Ltd falling/rising?

14-Feb-2026

As of 14-Feb, Source Natural Foods & Herbal Supplements Ltd's stock price has risen to 129.00, reflecting a 1.57% increase due to a strong opening and high volatility, despite overall declines in the past week, month, and year. Increased investor participation is evident, but the stock remains below its moving averages, indicating potential weaknesses.

As of 14-Feb, Source Natural Foods & Herbal Supplements Ltd is experiencing a rise in its stock price, currently at 129.00, reflecting an increase of 2.0 (1.57%). This upward movement can be attributed to several factors observed today. Notably, the stock opened with a significant gain of 10.24%, reaching an intraday high of Rs 140. Additionally, the stock has outperformed its sector by 2.61%, indicating positive market sentiment relative to its peers.<BR><BR>Despite the overall negative performance in the past week, month, and year, where the stock has shown declines of -3.73%, -7.86%, and -23.67% respectively, today's trading activity has been characterized by high volatility, with an intraday volatility of 5.24%. This suggests that while the stock has faced challenges, there is a notable increase in investor participation, as evidenced by a dramatic rise in delivery volume by 1002.01% compared to the 5-day average.<BR><BR>However, it is important to note that the stock is currently trading below its moving averages across various time frames, which may indicate underlying weaknesses. Nonetheless, the combination of a strong opening, high volatility, and increased investor interest has contributed to the stock's rise today.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with a 3.56% CAGR growth in Operating Profits over the last 5 years

 
2

Below par performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 90 Cr (Micro Cap)

stock-summary
P/E

28.00

stock-summary
Industry P/E

33

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.01

stock-summary
Return on Equity

13.33%

stock-summary
Price to Book

3.66

Revenue and Profits:
Net Sales:
20 Cr
(Quarterly Results - Dec 2025)
Net Profit:
1 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-7.86%
0%
-7.86%
6 Months
-14.26%
0%
-14.26%
1 Year
-23.67%
0%
-23.67%
2 Years
43.14%
0%
43.14%
3 Years
-6.49%
0%
-6.49%
4 Years
20.56%
0%
20.56%
5 Years
-25.17%
0%
-25.17%

Source Natural for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Announcements stock-summary

Incorporation Of Wholly Owned Subsidiary Company

11-Feb-2026 | Source : BSE

Incorporation of Wholly Owned Subsidiary Company.

Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended December 31 2025.

09-Feb-2026 | Source : BSE

Source Natural Foods And Herbal Supplements Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Unaudited Financial Results for the quarter ended December 31 2025.

Announcement Under Regulation 30 (LODR) 2015 - Outcome Of Board Meeting For Proposed Incorporation Of A Wholly-Owned Subsidiary.

12-Jan-2026 | Source : BSE

Outcome of Board Meeting - Proposed Incorporation of a Wholly-owned Subsidiary

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
22.84%
EBIT Growth (5y)
3.56%
EBIT to Interest (avg)
3.51
Debt to EBITDA (avg)
0.52
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
1.30
Tax Ratio
23.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
20.54%
ROE (avg)
15.66%

Valuation key factors

Factor
Value
P/E Ratio
28
Industry P/E
33
Price to Book Value
3.71
EV to EBIT
18.53
EV to EBITDA
15.13
EV to Capital Employed
3.69
EV to Sales
1.50
PEG Ratio
1.65
Dividend Yield
NA
ROCE (Latest)
18.41%
ROE (Latest)
13.33%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 0 Schemes

FIIs

Held by 0 FIIs

Promoter with highest holding

Sriveda Sattva Private Limited (74.37%)

Highest Public shareholder

Guttikonda Vara Lakshmi (2.96%)

Individual Investors Holdings

18.68%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 19.76% vs 40.08% in Sep 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 17.14% vs 11.11% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "20.30",
          "val2": "16.95",
          "chgp": "19.76%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1.53",
          "val2": "1.36",
          "chgp": "12.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.15",
          "val2": "0.16",
          "chgp": "-6.25%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "0.82",
          "val2": "0.70",
          "chgp": "17.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "7.54%",
          "val2": "8.02%",
          "chgp": "-0.48%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Standalone) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 57.79% vs 47.63% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 5.56% vs 173.91% in Sep 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "29.05",
          "val2": "18.41",
          "chgp": "57.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.62",
          "val2": "2.26",
          "chgp": "15.93%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.32",
          "val2": "0.26",
          "chgp": "23.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "1.33",
          "val2": "1.26",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "9.02%",
          "val2": "12.28%",
          "chgp": "-3.26%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Standalone) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is 71.00% vs 40.99% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2025 is -5.70% vs 60.56% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "49.35",
          "val2": "28.86",
          "chgp": "71.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4.15",
          "val2": "3.92",
          "chgp": "5.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.47",
          "val2": "0.46",
          "chgp": "2.17%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.15",
          "val2": "2.28",
          "chgp": "-5.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "8.41%",
          "val2": "13.58%",
          "chgp": "-5.17%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Standalone) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 64.54% vs 38.09% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 66.67% vs -17.92% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "44.92",
          "val2": "27.30",
          "chgp": "64.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.15",
          "val2": "4.47",
          "chgp": "15.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.62",
          "val2": "0.21",
          "chgp": "195.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.05",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "2.90",
          "val2": "1.74",
          "chgp": "66.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.46%",
          "val2": "16.37%",
          "chgp": "-4.91%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Standalone) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
20.30
16.95
19.76%
Operating Profit (PBDIT) excl Other Income
1.53
1.36
12.50%
Interest
0.15
0.16
-6.25%
Exceptional Items
0.00
0.00
Standalone Net Profit
0.82
0.70
17.14%
Operating Profit Margin (Excl OI)
7.54%
8.02%
-0.48%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 19.76% vs 40.08% in Sep 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Dec 2025 is 17.14% vs 11.11% in Sep 2025

Half Yearly Results Snapshot (Standalone) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
29.05
18.41
57.79%
Operating Profit (PBDIT) excl Other Income
2.62
2.26
15.93%
Interest
0.32
0.26
23.08%
Exceptional Items
0.00
0.00
Standalone Net Profit
1.33
1.26
5.56%
Operating Profit Margin (Excl OI)
9.02%
12.28%
-3.26%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 57.79% vs 47.63% in Sep 2024

Direction Arrows
Standalone Net Profit

Growth in half year ended Sep 2025 is 5.56% vs 173.91% in Sep 2024

Nine Monthly Results Snapshot (Standalone) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
49.35
28.86
71.00%
Operating Profit (PBDIT) excl Other Income
4.15
3.92
5.87%
Interest
0.47
0.46
2.17%
Exceptional Items
0.00
0.00
Standalone Net Profit
2.15
2.28
-5.70%
Operating Profit Margin (Excl OI)
8.41%
13.58%
-5.17%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2025 is 71.00% vs 40.99% in Dec 2024

Direction Arrows
Standalone Net Profit

YoY Growth in nine months ended Dec 2025 is -5.70% vs 60.56% in Dec 2024

Annual Results Snapshot (Standalone) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
44.92
27.30
64.54%
Operating Profit (PBDIT) excl Other Income
5.15
4.47
15.21%
Interest
0.62
0.21
195.24%
Exceptional Items
0.00
-0.05
100.00%
Standalone Net Profit
2.90
1.74
66.67%
Operating Profit Margin (Excl OI)
11.46%
16.37%
-4.91%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 64.54% vs 38.09% in Mar 2024

Direction Arrows
Standalone Net Profit

YoY Growth in year ended Mar 2025 is 66.67% vs -17.92% in Mar 2024

stock-summaryCompany CV
About Source Natural Foods & Herbal Supplements Ltd stock-summary
stock-summary
Source Natural Foods & Herbal Supplements Ltd
Micro Cap
Pharmaceuticals & Biotechnology
Source Natural Foods &Herbal Supplements Limited was formerly incorporated as Inwinex Pharmaceuticals Limited in 1995. The Company name was then changed from Inwinex Pharmaceuticals Limited to Source Natural Foods &Herbal Supplements Limited in 2011-12. The Company engages in the pharmaceutical business in India. It provides allopathic and ayurvedic formulations. Its principal products include Organic Ashwagandha, Organic Triphala, and Organic Satavari Tablets.
Company Coordinates stock-summary
Company Details
201 2nd Floor Sumeru Towers, 54/46 39 Jayanagar 4th Block Bangaluru Karnataka : 560041
stock-summary
Tel: 91-80-26087733
stock-summary
info@source-natural.com
Registrar Details
Venture Capital & Corporate Investments Ltd , 12-10-167,, MIG- 167,, Bharat Nagar Colony, Hyderabad